Last edition
News about "Molecular Therapeutics"
US FDA Grants Orphan Drug Designation to IFx-2.0 of TuHURA Biosciences
TuHURA Biosciences has received FDA Orphan Drug Designation for IFx-2.0 to treat stage IIB–IV cutaneous melanoma, based on data from its completed Phase I study published in Molecular Therapeutics.
Molecular Therapeutics | 04/02/2026 | By News Bureau | 140
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members